Tigulixostat is under clinical development by LG Chem and currently in Phase III for Gouty Arthritis (Gout). According to GlobalData, Phase III drugs for Gouty Arthritis (Gout) have a 56% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how Tigulixostat’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Tigulixostat (xanthine oxidase inhibitor) is under development for the treatment of gout which is associated with hyperuricemia. It is administered through oral route as a capsule. The drug candidate targets the enzyme xanthine oxidase. The drug is a new chemical entity (NCE). It was also under development for the treatment of gout and hyperuricemia in Korea.
LG Chem overview
LG Chem, a subsidiary of LG Corp, is a chemical manufacturer. The company manufactures and markets petrochemicals, IT and electronic materials, and energy solutions. Its product portfolio comprises polyvinyl chloride (PVC), ethylene, propylene, butadiene, benzene, polarizer, glass substrate, semiconductor materials and RO membranes, among others. It also offers growth hormone, vaccine, anti-diabetic products, and manufactures and supplies display and battery materials for LCD photoresist, OLED materials, battery materials and others. It owns and operates manufacturing facilities in Daesan, Yeosu, Ochang, Cheongju, Ulsan, Naju, Iksan, Paju and Gimcheon. The company has operations in China, India, Germany, the US, Vietnam, Brazil, Taiwan, Hong Kong and Poland, among others. LG Chem is headquartered in Seoul, South Korea.
For a complete picture of Tigulixostat’s drug-specific PTSR and LoA scores, buy the report here.